Agenus Inc
AGEN3.840USD
+0.150+4.07%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
115.22MMarket Cap
LossP/E TTM
More Details of Agenus Inc Company
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc Info
Ticker SymbolAGEN
Company nameAgenus Inc
IPO dateFeb 04, 2000
CEODr. Garo H. Armen, Ph.D.
Number of employees316
Security typeOrdinary Share
Fiscal year-endFeb 04
Address3 Forbes Rd
CityLEXINGTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02421-7305
Phone17816744400
Websitehttps://agenusbio.com/
Ticker SymbolAGEN
IPO dateFeb 04, 2000
CEODr. Garo H. Armen, Ph.D.
Company Executives of Agenus Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
By RegionUSD
Name
Revenue
Proportion
United States
25.16M
97.95%
Rest of World
526.00K
2.05%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
Shareholding Stats
Updated: an hour ago
Updated: an hour ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.06%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
Other
82.38%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.06%
Invus Public Equities Advisors, LLC
3.34%
B. Riley Financial, Inc
2.38%
Morgan Stanley & Co. LLC
2.26%
Millennium Management LLC
1.58%
Other
82.38%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.87%
Investment Advisor/Hedge Fund
4.62%
Research Firm
4.39%
Hedge Fund
2.84%
Individual Investor
1.76%
Venture Capital
0.19%
Family Office
0.17%
Bank and Trust
0.09%
Other
68.07%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
325
9.55M
29.96%
-3.46M
2025Q2
332
9.29M
33.90%
-3.65M
2025Q1
345
9.68M
35.51%
-3.04M
2024Q4
351
8.87M
37.81%
-3.86M
2024Q3
360
8.97M
41.48%
-3.09M
2024Q2
356
9.47M
44.86%
-4.33M
2024Q1
365
10.95M
52.48%
-2.79M
2023Q4
382
11.94M
62.90%
-111.48K
2023Q3
392
12.65M
70.00%
-689.92K
2023Q2
391
12.38M
73.61%
-974.75K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
2.53M
7.95%
-16.81K
-0.66%
Jun 30, 2025
Invus Public Equities Advisors, LLC
1.06M
3.34%
+564.25K
+112.85%
Jun 30, 2025
B. Riley Financial, Inc
756.96K
2.38%
+756.96K
--
Dec 31, 2024
Morgan Stanley & Co. LLC
719.75K
2.26%
+350.35K
+94.84%
Jun 30, 2025
Millennium Management LLC
504.51K
1.58%
+504.51K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
489.68K
1.54%
-1.12M
-69.54%
Jun 30, 2025
Marshall Wace LLP
432.48K
1.36%
+432.48K
--
Jun 30, 2025
AQR Capital Management, LLC
430.88K
1.35%
-10.60K
-2.40%
Jun 30, 2025
BofA Global Research (US)
420.68K
1.32%
+220.33K
+109.97%
Jun 30, 2025
Armen (Garo H.)
338.69K
1.06%
+7.51K
+2.27%
Sep 19, 2025
View more
Related ETFs
Updated: 18 hours ago
Updated: 18 hours ago
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Date
Type
Ratio
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
